Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.  He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.

He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983.  He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM.  His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine.  Oncology and infectious diseases are his major fields for research.  He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM.  Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy.  He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.

He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017.  He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).

Employment

• 2016-present, Coordinator of the outpatient clinics for the management of polytherapies in HIV-infected patients, L. Sacco University Hospital, Milano, Italy
• 2004-2013, Component (Pharmacologist) of the Ethical Committee of the Scientific Institute E. Medea, Bosisio Parini, Lecco, Italy
• 2003-2008, Component (Pharmacologist) of the Ethical Committee of the Bolognini Hospital of Seriate, Bergamo, Italy
• 2004-2008, Head, Unit of Pharmacology and Pharmacogenetics, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
• 1997-2003, Research fellow, Mario Negri Institute for Pharmacological Research, Bergamo, Italy

Academic commitments

• 2010-present, Assistant professor in Pharmacology, Faculty of Medicine, University of Milano, Italy
• 2003-2011, Assistant Professor, Master in Transplant Medicine, University of Milano Bicocca, Italy
• 2005-2008, Educational coordinator, Maastricht University (Belgium), within the Research Elective Agreement with the Mario Negri Institute for Pharmacological Research, Bergamo, Italy
• 2004-2008, Assistant Professor, Master in Clinical Research, University of Milano, Italy
• 2013-2017, Assistant Professor, Master in Pharmacovigilance and Pharmacoepidemiology, University of Naples, Italy

Education & Certification:

• 1984-1989, High school diploma in Chemistry (Bergamo, Italy)
• 1990-1995, Pharmacy Degree (University of Milano, Italy)
• 1997-2000, Post-graduation specialization in Pharmacological Research (Mario Negri Institute for Pharmacological Research, Bergamo, Italy)
• 1998-2001, Post-degree Specialization in Pharmacology (University of Milano, Italy)
• 2001-2005, PhD in Biomedical Sciences (Open University, London, UK)

Professional Activities

• 2005-present, International Association of Therapeutic Drug Monitoring and Clinical Toxicology
• 2006-present, Italian Society of Pharmacology
• 2016-present, Italian Society of Infectious Diseases and Tropical Medicine
• 2019-present, European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• 2009-2016, American College of Clinical Pharmacology
• 2018-present, Italian Federation of Human and Animal Mycology

Awards

• 2001, Winner of the E. Cofferati award for the research activity in the field of immunosuppressant pharmacology
• 2010, Winner of the D.E.I. Onlus Foundation award for the best emerging profiles in the field of clinical pharmacology

Publications / scientific activities

• Author of nearly 200 publications on peer reviewed indexed international journals, cited more than 5000 times, H-index: 35
• 7 book chapters
• Invited speaker for nearly 50 international congresses
• Invited speaker for nearly 200 national congresses
• Referee activities for dozens of indexed international journals (> 500 manuscripts reviewed)
• Member of the editorial board of European Journal of Drug Metabolism and Pharmacokinetics
• Member of the editorial board of Therapeutic Drug Monitoring
• Vice chair of the anti-infective committee within the IATDMCT society
• Member of the ESCMID PK/PD of Anti-Infectives Study Group
• Member of the board of directors of the Italian Federation of Human and Animal Mycology

Main clinical/research activities

• Therapeutic drug monitoring (mainly anti-infective agents, immunosuppressants, and central nervous system drugs)
• Pharmacokinetic studies both in healthy volunteers and in patients
• Application of pharmacogenetics as diagnostic tool for the optimization of drug therapies
• Antimicrobial stewardship
• Study and assessment of potential drug-drug interactions in real life settings
• Evaluation of potential inappropriate drug prescribing in fragile patients (deprescribing)
• Development and validation of analytical methods for the quantification of drugs in different biological matrices

Vision Statement
I envisage the future of the IATDMCT society as the key player for the tailoring of drug therapy in increasingly complicated patients (elderly, with comorbidities and heavy polypharmacy) at the bedside, taking advantage from the presence of active members with excellences and expertise in several fields. The accomplishment of this task requires, however, a day-by-day, two-way strict collaboration with specialists from different medical disciplines. In other words, the labs need to meet/match the clinics!

Employment

• 2018-present, Medical Head Therapeutic Drug Monitoring, Synlab Holding Germany GmbH, MVZ Leinfelden-Echterdingen
• 2003-2018, Senior scientist and Head TDM/Tox Section, Institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany
• 1999-2002, Resident, Dept. of Clinical Chemistry, University Göttingen, Germany
• 1995-1999, Postdoctoral fellow, Dept. of Clinical Chemistry, University Göttingen, Germany
• 1992-1995, Resident Dept. of Clinical Chemistry, University Sofia, Bulgaria
• 1991-1992, Resident Dept. Internal Medicine, University Sofia, Bulgaria

Education & Certification:

• Academic Degrees:
  • Dr. med. University Göttingen, Germany, 2002
  • D-r (BG)., University Sofia, Bulgaria, 1990
• Professional Registrations:
  • Fellow European Board of Laboratory Medicine/Medical Biopathology (F.E.B.L.M./M.B.), 2013
  • Clinical Pathology Consultant, 1996

Professional Activities

• Professional Society Memberships:
  • Vereinte Deutsche Gesellschaft für Laboratoriumsmedizin und Klinische Chemie (DGKL)
  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • Transplantation Society
  • Bulgarian Academy of Sciences and Arts
• Publications:
  • 115 articles contributed to scientific journals and book chapters on the following topics: therapeutic drug monitoring, drug metabolism, drug toxicity, development and evaluation of analytical methods, organ function tests, biomarkers of drug effects.
• Stipends and Awards:
  • 2015 Grant from the Federal Ministry of Education and Research “Validation of GcfDNA based diagnostic test to detect organ damage after kidney transplantation”
  • 2011 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Analytical validation of biomarker assays in transplantation medicine
  • 2005 Young Investigator Award of the International Society for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
  • 2004 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Acyl glucoronides of mycophenolic acid
  • 2002 Grant of the University Göttingen, Germany, Acyl glucuronide of mycophenolic acid
  • 1998 Stipend Volkswagen Foundation, Germany, Metabolism of immunosuppressants
  • 1996 Stipend Otvoreno Obschtestvo, Bulgaria, Pharmacokinetics of Taxol
  • 1995 Tempus Phare stipend of the EU, Therapeutic Drug Monitoring
• Varia:
  • Secretary IATDMCT (2017 - )
  • Director of Education IATDMCT (2015 - 2017)
  • Vice-Chair IATDMCT Communication Committee (2011 - 2017)
  • Member of the IATDMCT Communication Committee (2011 -)
  • Member of the IATDMCT Biomarkers in transplantation Working Group (2009 - )
  • Coordinator “TDM of Everolimus” Consensus Project (2013-2016)
  • Past-Chair of the IATDMCT Immunosuppressive Drugs Scientific Committee (2013–2015)
  • Past Editor in Chief of the IATDMCT Newsletter “Compass” (2009 – 2015)
  • Member of the LOC of the 11th IATDMCT Congress, 2011, Stuttgart, Germany
  • Reviews Editor and Member the Editorial Board of Therapeutic Drug Monitoring (TDM)
  • Member of the Editorial Boards of Clinical Mass Spectrometry and Journal of Laboratory Medicine
  • Reviewer of publication for: Journal of Chromatography, Clinical Chemistry, Clinical Biochemistry, Clinica Chimica Acta, Transplant International, etc.

Why would you be a good member of IATDMCT Council
As a longstanding member of IATDMCT for (>20 years) and somebody who had have the privilege to serve this Association at various positions over the past years I am glad to know many IATDMCT members and enjoy networking within IATDMCT. I hope that I have been able to convince with organizational-, communication-skills and persistence during my services and will be honored to continue my efforts for IATDMCT as a member of the Council.

Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.

For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.

Employment:

• Sep 2012-Present: Forensic Medicine and Science (FMS), University of Glasgow, UK
• Forensic Toxicologist

• Dec 2002-Sep 2012: Analytical Services International (ASI), St George’s, University of London, UK
  Senior Scientist in Clinical and Forensic Toxicology

Education & Certification:

• Sep 1996-June 2002: University of Strathclyde, Glasgow, UK
  MSci in Forensic and Analytical Chemistry

Professional Activities:

• Member of International Association of TDM & Clinical Toxicology (IATDMCT)
  Sep 2017-Present: Treasurer of IATDMCT
  Jan 2012-Dec 2017: Communications Committee (CC) Chair
  (activities coordinated by CC: E-News, Social Media, Blog, Website / Resources Area, Compass etc)
  Oct 2011-Oct 2015: Young Scientist Committee (YSC) Chair
  (coordinated all YS activities: Congress YS workshops/symposia, social events and awards, and all non-Congress educational activities)
  Sep 2007-Oct 2015: Compass Associate Editor
  Apr 2005-Oct 2011: Young Scientist Committee (YSC) Vice-Chair
• Member of The International Association of Forensic Toxicologists (TIAFT)
• Member of UK and Ireland Association of Forensic Toxicologists (UKIAFT)
• Member of London Toxicology Group (LTG)
• Member of Royal Society of Chemistry (MRSC)
• Invited speaker and presented at national and international meetings
• Contributed to to several peer-reviewed publications and book chapters
• Visiting Lecturer, Queen Mary, University of London (Oct-2010-Present)

Dr. Teun van Gelder is an internist-nephrologist and clinical pharmacologist. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time.

Between 2000 and 2019 he worked in the Departments of Hospital Pharmacy and Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands. In 2010, at Erasmus Medical Center he was appointed Professor in Clinical Pharmacology. His research at the Erasmus Medical Center was focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology & Biopharmacy, the secretary of the Dutch Society for Transplantation, and the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.

In December 2019 Teun van Gelder accepted a new position in Leiden University Medical Center (LUMC). He was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development. In his role as an experienced internist – clinical pharmacologist Teun will make an important contribution to Academic Pharma.

Current Appointments

• Senior Specialist in Clinical Microbiology and Infectious Diseases St. Vincent's Hospital, Sydney (1985 - to date)
• Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group, St. Vincent’s Hospital, Sydney (2012 – to date)
• Visiting Medical Officer St. Vincent's Private Hospital, Sydney (1985 – to date)
• Visiting Medical Officer Sacred Heart Hospice, Sydney (1985 – to date)
• Conjoint Associate Professor, School of Medicine, University of New South Wales (2000 – to date)
• Adjunct Professor, Faculty of Science University of Technology, Sydney (2002 -to date)
• Associate Editor, Transplantation (2014 – to date)

Certifications

• Fellow of the Royal College of Pathologists of Australasia (FRCPA) 1986
• Fellow of the Royal Australasian College of Physicians (FRACP) 1985
• Bachelor of Medicine and Bachelor of Surgery, Honours Class I 1977
• Bachelor of Science (Medicine) Honours Class I 1974

Current Memberships - Professional Societies

• Royal Australasian College of Physicians
• Royal College of Pathologists of Australasia
• Australasian Society for Infectious Diseases
• Australasian Society for HIV Medicine
• American Society for Microbiology
• Australasian Society for Antimicrobials
• Infectious Diseases Society of America
• International Society for Heart and Lung transplantation
• International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• Transplant Infectious Diseases
• European Society for Clinical Microbiology and Infectious Diseases
• The Transplant Society
• Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

• 1986- Member, Drug and Therapeutics Committee, St. Vincent's Hospital
• 1988 - Accreditor, National Association of Testing Authorities
• 1989-97 Member, N.S.W. State Committee, Royal Australasian College of Physicians
• 1990- Examiner, Royal Australasian College of Pathologists
• 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
• 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
• 1997-99 President, Australasian Society for HIV Medicine
• 2000-10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
• 2009-13 Co-chair, Australian and New Zealand Mycoses Interest Group
• 2010 - Examiner, Royal Australasian College of Physicians
• 2012- Scientific Committee member (HIV and Infectious Diseases), International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• 2012- Scientific Committee member, International Society for Heart and Lung Transplantation • 2012- Scientific Committee member, Transplant Infectious Diseases
• 2013- President, Transplant Infectious Diseases
• 2013- Board Member, Medical Advances without Animals
• 2014 - Visiting Lecturer, The Academy of Medicine, Singapore
• 2014- Visiting International Professor, Royal College of Pathologists of Australasia

• Approximately 160 publications in refereed journals
• Joint lead, IATDMCT Guidelines on TDM of Echinocandins
• Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device. The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients. (In press).
• Proposer and Co-Convener – joint IATDMCT/TID/The Transplant Society (TTS) Conference, Hong Kong, 2016 in conjunction with TTS Conference
• Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014), ISHAM (Melbourne 2015)
• Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013) and Penang (2014).
• Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
• Coordinator of the Clinical Stream at the forth-coming ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
• Reviewer of approximately 15 manuscripts per year for the past 5 years in local and international journals

Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.

He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS.  He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.

Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.

He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.

Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics,  therapeutic drug monitoring, clinical trial design and conduct.

Dr. Ryuji Kato is an Associate Professor of Cardiovascular Pharmacotherapy and Toxicology at Osaka University of Pharmaceutical Sciences, Osaka, Japan. He completed his master’s degree in 2000 at Osaka University and began his career as a pharmacist at the Yokkaichi Social Insurance Hospital (Mie, Japan). He then moved to Osaka University of Pharmaceutical Sciences as an Assistant Professor. In 2008, he received his PhD in Pharmaceutical Sciences.

His research interests primarily include the appropriate use of pharmaceutical products. He has conducted extensive research on pharmacokinetics, drug-drug interactions (chelation complexes, drug-drug interactions on cytochrome P450 or via transporters), and serious adverse side effects (QT prolongation, drug induced liver injury, interstitial pneumonia, Stevens-Johnson syndrome, and toxic epidermal necrolysis).

He is the author or co-author of approximately 70 peer-reviewed manuscripts. Dr. Kato is a member of the following academic societies: International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Japanese Society of Therapeutic Drug Monitoring (JSTDM), Society of Toxicology (SOT), Pharmaceutical Society of Japan, and Japanese Society of Nephrology and Pharmacotherapy (JJNP). He has been a member of IATDMCT Communication Committee since 2015 and is an inspector for JSTDM.

Christophe Stove, PharmD, PhD, is Associate Professor at the Department of Bioanalysis at Ghent University (Belgium). After a cell and molecular biology-oriented PhD and postdoc, he embarked upon bioanalysis in 2007 and became head of the Laboratory of Toxicology at the Faculty of Pharmaceutical Sciences in 2014. Besides teaching several courses, he directs the Lab’s service activities (forensic toxicology and reference lab activities (Ref4U)) and steers the research. The latter covers applied cell biology, as well as bioanalysis, with topics linked to the development of bio-assays as an alternative drug screening approach in forensic toxicology, to vitamer analysis, or to microsampling applications and associated challenges. He has over 125 publications, many of which in leading journals, and has an h-index of 28. He is active as a Board/Council Member of several national and international organizations (including TIAFT and IATDMCT).

Nicolas Venisse got his PharmD from the University of Bordeaux, France in 1999. He completed his PhD in Pharmaceutical Sciences at the University of Poitiers. He also received accreditation to supervise research from the University of Poitiers. He is expert at the court of appeal of Poitiers.

He currently works at the Toxicology and Pharmacokinetics department at the University Hospital of Poitiers. He is also a member of the HEDEX (Health - Endocrine Disruptors – Exposome) research group at the Clinical Investigation Center of Poitiers (CIC INSERM 1402).

He is a member of several professional organizations including : Société Française de Pharmacologie et Thérapeutique and IATDMCT. He is the current chair of the Toxicology and Environmental Health scientific committee at IATDMCT. He is a member of the French National Academy of Pharmacy (Académie Nationale de Pharmacie), Environmental Health Committee (6éme section, Santé Environnementale).

He has over 40 peer-reviewed publications and 10 book chapters. His areas of expertise include: environmental toxicology, pharmaco- and toxico-kinetics, bioanalysis and PK/TK modeling.

Employment

• 01/2020 – present: Director of Toxicology Counseling Center of Hunan Province (TCCH), China
• 01/2019 – present: Deputy Director of Scientific Research Department, the Second Xiangya Hospital of Central South University, China
• 09/2017 – present: Associate Professor of Pharmacy, the Second Xiangya Hospital of Central South University, China
• 05/2013 – 06/2014: Postdoctoral Research Fellow, University of Illinois at Chicago, USA
• 07/2010 – 08/2017: Clinical Pharmacist, the Second Xiangya Hospital of Central South University, China

Education & Certification

• 2010: Ph.D. in Pharmacology, Central South University, China

Professional Activities

• Executive and committee positions held:
  • 09/2019 – present: Councilor of IATDMCT
  • 10/2018 – present: Chair of Young Scientist Committee, Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society (CHINA-TDM)
  • 09/2018 – present: Member of TDM in Oncology Committee, IATDMCT
  • 09/2016 – present: Member of Young Scientist Committee, IATDMCT
  • 07/2015 – present: Member of Pharmacometrics Committee, Chinese Pharmacological Society
• Activities in IATDMCT:
  • [Co-Chair of Symposium, Invited speaker]. IATDMCT Congress 2019; Sept 22-26, 2019, Foz do Iguassu, Brazil
  • [Executive chair]. The First CHINATDM-IATDMCT Young Scientist Joint Symposium at the 9th International Xiangya Clinical Pharmacy Forum; Sept 5-7, 2019, Changsha, China
  • [Guest speaker]. The Third JSTDM-IATDMCT Young Scientist Joint Symposium at the 36th Annual Meeting of the Japanese Society of Therapeutic Drug Monitoring; May 25-26, 2019, Tokyo, Japan
  • [Oral presentation]. IATDMCT Congress 2018; Sept 16-19, 2018, Brisbane, Australia
  • [Poster presentation]. IATDMCT Congress 2017; Sept 24-27, 2017, Kyoto, Japan
• Publications:
  • Published 50 research papers in Science Citation Index journals

Teun van Gelder is a Professor in Clinical Pharmacology, as well as an internist-nephrologist and clinical pharmacologist in the Department of Hospital Pharmacy and Department of Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands.

Professor van Gelder was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a postdoctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr Randall E Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during that time.

Professor van Gelder’s current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring. He is the chairman of the Dutch Society for Clinical Pharmacology and president-elect of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. 

Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.

She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.

Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.  He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.

He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983.  He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM.  His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine.  Oncology and infectious diseases are his major fields for research.  He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM.  Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy.  He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.

He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017.  He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).

Dr. med. Maria Shipkova received her medical education at the Medical University, Sofia, Bulgaria, where she specialized in Laboratory Medicine. In 1992 she joined the TDM laboratory headed by Prof. Dobrin Svinarov, Chair for Clinical Laboratory, Sofia. In 1995 Dr. Shipkova was awarded a Tempus Phare postdoctoral fellowship from the European Union to broaden her education in therapeutic drug monitoring at the Department of Clinical Chemistry, Georg-August-University, Göttingen, under its Director, Prof Michael Oellerich. At the conclusion of this appointment she remained in Göttingen as a resident and was involved in a variety of routine and research activities in the field of transplantation and immunosuppressive drug monitoring. In 2003 Dr. Shipkova moved to Stuttgart, where she now pursues her work in the field of the therapeutic drug monitoring as a Senior Scientist at the institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart. She is responsible for the therapeutic drug monitoring/toxjcology section.

In 2005 Maria Shipkova was awarded with the Young Investigator Award of the International Society for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Her research interests are focused on drug metabolism & drug toxicity, development & evaluation of analytical methods, and most recently biomarkers as a tool to optimize immunosuppressive therapy.

Dr. Shipkova has authored over 100 peer- reviewed publications and has supervised several doctoral theses and post-doc fellows in the field of the therapeutic drug monitoring. She was the Chair of the IATDMCT immunosuppressive Drugs Scientific Committee (2013-2015) and IATDMCT Director of Education (2015 – 2017). Dr Shipkova is currently Vice-Chair of the Communications Committee of the IATDMCT. She has held the following positions: Coordinator "TDM of Everolimus" Consensus Project (2013-2016), Member of the IATDMCT Biomarkers in transplantation Working Group (2009 -), Associated member of the Bulgarian Academy of Science and Arts, past Editor in Chief of the IATDMCT Newsletter "Compass" (2009 - 2015).

Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.

For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.

Employment:

• Sep 2012-Present: Forensic Medicine and Science (FMS), University of Glasgow, UK
• Forensic Toxicologist

• Dec 2002-Sep 2012: Analytical Services International (ASI), St George’s, University of London, UK
  Senior Scientist in Clinical and Forensic Toxicology

Education & Certification:

• Sep 1996-June 2002: University of Strathclyde, Glasgow, UK
  MSci in Forensic and Analytical Chemistry

Professional Activities:

• Member of International Association of TDM & Clinical Toxicology (IATDMCT)
  Sep 2017-Present: Treasurer of IATDMCT
  Jan 2012-Dec 2017: Communications Committee (CC) Chair
  (activities coordinated by CC: E-News, Social Media, Blog, Website / Resources Area, Compass etc)
  Oct 2011-Oct 2015: Young Scientist Committee (YSC) Chair
  (coordinated all YS activities: Congress YS workshops/symposia, social events and awards, and all non-Congress educational activities)
  Sep 2007-Oct 2015: Compass Associate Editor
  Apr 2005-Oct 2011: Young Scientist Committee (YSC) Vice-Chair
• Member of The International Association of Forensic Toxicologists (TIAFT)
• Member of UK and Ireland Association of Forensic Toxicologists (UKIAFT)
• Member of London Toxicology Group (LTG)
• Member of Royal Society of Chemistry (MRSC)
• Invited speaker and presented at national and international meetings
• Contributed to to several peer-reviewed publications and book chapters
• Visiting Lecturer, Queen Mary, University of London (Oct-2010-Present)

Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.

From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland. Since May 2014 head of the laboratory medicine at the University Hospital Basel, Switzerland.

Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of over 150 peer-reviewed publications, 8 book chapters and over 60 published oral or poster presentations.

Dr Rentsch is a member of and serves on committees for several professional organizations including: Swiss Society of Clinical Chemistry (SSCC), the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh) and IATDMCT. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.

Dr. Erik van Maarseveen got his Pharmacy Degree in 2005 and started his career as a pharmacist at the Gouda Hospital (The Netherlands). That same year he obtained the Certificate of Fundamentals of Business & Economics for Beta’s as part of the Master program “Business and Economics for Beta’s” at Utrecht University.  His 4-year-training as a hospital pharmacist commenced in 2006 at Central Hospital Pharmacy, The Hague and the Gouda Hospital. Dr. van Maarseveen has been working as a registered hospital pharmacist since 2010 at the University Medical Center Utrecht (The Netherlands), where he leads the therapeutic drug monitoring and toxicology laboratory which is equipped with GC, HPLC, UPLC, LC-MSMS and Orbitrap-LCMS techniques.

Dr. van Maarseveen and his team develop bio-analytical assays primarily for therapeutic drug monitoring and clinical toxicology purposes with the ultimate goal to improve treatment outcomes. Directly after he obtained his PhD on optimizing treatment of once daily dosed aminoglycosides and continuously infused vancomycin, he embarked on his clinical pharmacologist training, which he completed in 2016. Currently, his research focusses on clinical pharmacology and clinical mass spectrometry in solid organ and stem cell transplantation, infectious diseases, cystic fibrosis and oncology. Among others, he is co-applicant of a grant of the Dutch KiKa (Children Cancerfree) foundation awarded to investigate the pharmacology of conditioning agents in stem cell transplantation conditioning. Van Maarseveen is a member of the TDM in Oncology scientific committee of the IATDMCT association, chair of the special interest group on Transplantation and member of the committee on Analysis & Toxicology of the Dutch Association for Hospital Pharmacists. In 2016, he was installed as a board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology.

Furthermore, Dr van Maarseveen, who is in possession of a University Teaching Qualification,  teaches pharmacology, TDM and toxicology to both pharmacy and medical students at Utrecht University. Dr van Maarseveen has published over 35 peer-reviewed papers (https://www.researchgate.net/profile/Erik_Van_Maarseveen2) and acts as a reviewer for several clinical and pharmacology journals. In 2015 he was granted the award for best publication by the Dutch Association for Hospital Pharmacists.

Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.

He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.

Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics,  therapeutic drug monitoring, clinical trial design and conduct.

Current Appointments

• Senior Specialist in Clinical Microbiology and Infectious Diseases St. Vincent's Hospital, Sydney (1985 - to date)
• Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group, St. Vincent’s Hospital, Sydney (2012 – to date)
• Visiting Medical Officer St. Vincent's Private Hospital, Sydney (1985 – to date)
• Visiting Medical Officer Sacred Heart Hospice, Sydney (1985 – to date)
• Conjoint Associate Professor, School of Medicine, University of New South Wales (2000 – to date)
• Adjunct Professor, Faculty of Science University of Technology, Sydney (2002 -to date)
• Associate Editor, Transplantation (2014 – to date)

Certifications

• Fellow of the Royal College of Pathologists of Australasia (FRCPA) 1986
• Fellow of the Royal Australasian College of Physicians (FRACP) 1985
• Bachelor of Medicine and Bachelor of Surgery, Honours Class I 1977
• Bachelor of Science (Medicine) Honours Class I 1974

Current Memberships - Professional Societies

• Royal Australasian College of Physicians
• Royal College of Pathologists of Australasia
• Australasian Society for Infectious Diseases
• Australasian Society for HIV Medicine
• American Society for Microbiology
• Australasian Society for Antimicrobials
• Infectious Diseases Society of America
• International Society for Heart and Lung transplantation
• International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• Transplant Infectious Diseases
• European Society for Clinical Microbiology and Infectious Diseases
• The Transplant Society
• Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

• 1986- Member, Drug and Therapeutics Committee, St. Vincent's Hospital
• 1988 - Accreditor, National Association of Testing Authorities
• 1989-97 Member, N.S.W. State Committee, Royal Australasian College of Physicians
• 1990- Examiner, Royal Australasian College of Pathologists
• 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
• 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
• 1997-99 President, Australasian Society for HIV Medicine
• 2000-10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
• 2009-13 Co-chair, Australian and New Zealand Mycoses Interest Group
• 2010 - Examiner, Royal Australasian College of Physicians
• 2012- Scientific Committee member (HIV and Infectious Diseases), International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• 2012- Scientific Committee member, International Society for Heart and Lung Transplantation • 2012- Scientific Committee member, Transplant Infectious Diseases
• 2013- President, Transplant Infectious Diseases
• 2013- Board Member, Medical Advances without Animals
• 2014 - Visiting Lecturer, The Academy of Medicine, Singapore
• 2014- Visiting International Professor, Royal College of Pathologists of Australasia

• Approximately 160 publications in refereed journals
• Joint lead, IATDMCT Guidelines on TDM of Echinocandins
• Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device. The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients. (In press).
• Proposer and Co-Convener – joint IATDMCT/TID/The Transplant Society (TTS) Conference, Hong Kong, 2016 in conjunction with TTS Conference
• Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014), ISHAM (Melbourne 2015)
• Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013) and Penang (2014).
• Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
• Coordinator of the Clinical Stream at the forth-coming ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
• Reviewer of approximately 15 manuscripts per year for the past 5 years in local and international journals

Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.

He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS.  He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker control, simulation, and most importantly, use of models to optimize therapy for individual patients. He is a practicing pediatric infectious diseases specialist. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on anti-infective compounds, he has experience with other therapeutic areas.

Michael Neely is the Acting Chief of Infectious Diseases and Director of the Laboratory of Applied Pharmacokinetics and Bioinformatics (LAPKB) at the Children's Hospital of Los Angeles and an Associate Professor of Pediatrics and Clinical Scholar at the University of Southern California (USC) Keck School of Medicine. He created Pmetrics, a non-parametric and parametric population modeling and simulation package for R based on over four decades of work by members of LAPKB. He also created an R package for LAPKB’s BestDose software to optimize drug therapy for individual patients. He works with multidisciplinary faculty collaborators in the USC Departments of Pediatrics, Medicine, and Preventive Medicine, as well as in the School of Pharmacy.

Dr. Neely has a Master’s of Science in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He was a member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee and now periodically consults for the committee. He is a Regent of the American College of Clinical Pharmacology, a founding member of the International Society of Pharmacometrics, and an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He has been the PI on an NIH K23 training grant, two R01s, and is co-PI of a third R01, as well as co-investigator on numerous other NIH grants, with continuous NIH funding since 2007.

Michael Neely has published more than 100 peer-reviewed articles, mentored numerous visiting scholars, and is an invited speaker worldwide.

Employment

• PhD student
  • 1999-2003 Ghent University (Faculty of Medicine & Health Sciences)
• Postdoctoral researcher
  • 2004-2007 Ghent University (Faculty of Sciences)
  • 2007-2013 Ghent University (Faculty of Pharmaceutical Sciences)
• Assistant-Professor (‘Docent’)
  • Since Feb 2013 Ghent University (Faculty of Pharmaceutical Sciences)

Education & Certification:

• 1999 Pharmacist
• 2004 PhD in Medical Sciences

Professional Activities:

Activities specifically related to IATDMCT

• Meetings:
  • First meeting in Stuttgart in 2011
  • Prize for best poster/poster presentation at the 2011 meeting
  • Participated to the 2013 and 2015 meetings (always with an active contribution (oral and/or poster)
  • Will participate to the 2017 meeting
• Alternative Sampling Strategies Committee:
  • Member since 2011
  • Chair from 2011-2015
  • Vice-chair since 2015
  • Actively engaged in:
    • Organising workshops, roundtables, scientific sessions, etc. for the International Congresses in Salt Lake City, Rotterdam and Kyoto
    • Providing contributions to the Compass on a regular basis
• Organizer of a successful IATDMCT Satellite Symposium in 2015
  • Alternative Sampling Strategies in Toxicology and Therapeutic Drug Monitoring
  • 176 registrants from 22 countries
  • [insert bio image here]
• Young Scientist member
  • Active member since the start of membership
  • Co-represented young scientists at the 2015 meeting of the Japanese Society of Therapeutic Drug Monitoring
• Referee for the journal Therapeutic Drug Monitoring
• Core research activities align very well with the scope of IATDMCT

Teaching activities
Responsible for the following courses at Ghent University:

• Toxicology (2nd Master)
• General Toxicology (3rd Bachelor)
• Bioanalysis (Master)
• Chemical Criminalistics (Master)
• Drug Toxicity (Master)
• Supplements in Toxicology: advanced studies (MaNaMa Clinical Biology)
• Co-responsible for Bioanalytical Practical Course

Research Activities (general):

1. Publications: Summary:
   • 77 A1 articles published or in press; 2 proceedings; 1 Book as Editor, 4 Book Chapters
   • # (%) in different quartiles: Q1: 66% – Q2: 29% – Q3: 4% – Q4: 1%
     Average positioning: 20% - Median positioning: 18%
     # in top 10%: 20 (26%) - # in top 5 of a category: 14 (18%)
   • 51 articles as 1st, 2nd or last author
   • 1186 Times Cited (ISI Web of Knowledge → Web of Science, 01/03/2017)
   • Average Impact Factor: 4.497; Median Impact Factor: 3.436
   • h-index (# articles with # of citations): 21
2. Promotor of 4 defended PhD’s and >10 ongoing PhD’s
3. 3 main research lines can be distinguished:
   • Alternative sampling strategies (e.g. dried blood microsampling, hair analysis)
   • Development of bio-assays for monitoring of activation of G-protein coupled receptors
   • Analysis of vitamers (amongst which folates), their precursors and degradation products, in plant material and biological material (blood)
4. Referee for > 30 journals (currently about 1 review/week)
5. Involved in the activities (e.g. regional editor; member of scientific committees) of main international scientific organisations (e.g. TIAFT and IATDMCT); Former chair of the Alternative Sampling Strategies Committee of IATDMCT.
6. Organizer of intra-faculty conferences, as well as an international conference on “Alternative Sampling Strategies in Toxicology and Therapeutic Drug Monitoring” (Sep 2014, 176 registrants). Main co-organizer of the TIAFT2018 meeting, to be held in August 2018 in Ghent (anticipated number of attendants: 600-700).
7. > 100 oral and poster presentations at national and international conferences
8. Member of the reading or examination committee of >30 PhD theses (national & international)
9. Member of scientific societies:
   • Toxicological Society of Belgium and Luxemburg (BLT) (Board Member);
   • BelTox (Belgian Society of Toxicology and Ecotoxicology);
   • Belgian Environmental Mutagen Society (Board Member);
   • Belgian Society of Mass Spectrometry (BSMS);
   • American Chemical Society (ACS);
   • The International Association of Forensic Toxicologists (TIAFT);
   • International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT);
   • Belgisch Genootschap voor Farmaceutische Wetenschappen (BGFW);
   • Belgisch Genootschap voor Gerechtelijke Geneeskunde (BGGG).

Service Activities (external):

• Head of the Laboratory of Forensic Toxicology
  • Follow-up of routine casework in judicial cases since Jan 1st 2008
  • End responsible (lab director) since Sept 15, 2014
  • Provided many hundreds of reports to the Department of Justice
  • Expert witness in court
• Core member of the Forensic Institute of Ghent University (FI-UGent).
• Toxicological consultancy; ad hoc toxicological expertise (e.g. Superior Health Council, Fonds Medische Ongevallen).
• Involved in providing toxicological expertise in the train disaster at Wetteren (Belgium) (May 2013 - on-site expertise, scientific publications, part of the superior health council, report to federal minister of public health, …).
• Recognized by the Department of Justice as expert for determination of alcohol in cases of drunk driving (since Sept 4, 2014).
• Director of the ISO 17025/1595 accredited Reference Laboratory Ref4U, implementing reference measurement procedures for e.g. thyroid hormones and vitamin D.

Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.

She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.

Dr Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD theses and post-doc fellows. He is also head of Clinical Chemistry Department in the Cliniques universitaires St Luc, Brussels, in charge of the automated CoreLab platform as well as of the analytical biochemistry platform regrouping specific activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry and endocrinology (GC, HPLC, UPLC, LC-MSMS, GC-MS).

He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author of more than 180 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 200 conferences on invitation. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas. Pierre Wallemacq is the past-president of the Royal Belgian Society of Clinical Chemistry (SRBCC-KBVKC), and is the current president of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. He received the IATDMCT C.E. Pippenger award in 2011 for outstanding contribution to Therapeutic drug Monitoring, and was nominated member of the Royal Belgian Academy of Medicine (ARMB) in 2012.

Employment

• 2010- Professor in Clinical Pharmacology
  Internist-clinical pharmacologist, Dept Hospital Pharmacy, Erasmus Medical Center - Rotterdam - NL
  Internist-nephrologist, Dept Internal Medicine, Erasmus Medical Center - Rotterdam - Netherlands
• 2002-2010 Internist-clinical pharmacologist, Dept Hospital Pharmacy
  Internist-nephrologist, Dept Internal Medicine
  Both at Erasmus Medical Center - Rotterdam - The Netherlands
• 2000-2002 Head of the Renal Transplantation Unit - Dept Internal Medicine - Erasmus Medical Center
• 1998-1999 Post-doctoral fellow Dept Cardiothoracic Surgery -
  Laboratory for Transplantation Immunology, Stanford University - Palo Alto - USA
• 1996-1998 Internist-nephrologist, Erasmus Medical Center - Rotterdam - The Netherlands
• 1993-1996 Internist, Erasmus Medical Center - Rotterdam - The Netherlands
• 1988-1993 Resident Internal Medicine, Erasmus Medical Center - Rotterdam - The Netherlands
• 1987-1988 MD in (mandatory) Military Service

Education & Certification

• Clinical Pharmacology (certification: December 1, 2003)
  Trained at University Medical Center Nijmegen – Netherlands in 2002-2003
• Post-doctoral fellowship (Transplantation Immunology)
  Stanford University 1998-1999 (Professor Randall E Morris)
• Thesis (Erasmus University Rotterdam) date : May 15, 1996 PhD. Title of thesis "The role of anti Interleukin-2 receptor monoclonal antibody (BT563) in the prevention of acute rejection after organ transplantation"
• Nephrology (certification April 16, 1996)
  Trained at University Hospital Rotterdam 1995-1996
• Internal Medicine (certification May 1, 1993)
  Trained at University Hospital Rotterdam 1988-1993
• Medicine (certification as MD at Feb 20, 1987)
  Trained at Erasmus University Rotterdam 1980-1987 MD

Professional Activities

• Since 2003 member of IATDMCT.
• From 2005-2009 Councilor of IATDMCT
• From 2009-2013 Director of Education within Council of IATDMCT
• From 2009-2013 Chair of Immunosuppressive drugs committee of IATDMCT
• From 2009 - 2015 Secretary of Dutch Transplantation Society
• Since 2011 Chairman of Dutch Society for Clinical Pharmacology and Biopharmacy

Web-of-Science: 346 publications, H-index 39, with 6079 citations (as of March 2015)
Speaker at numerous conferences, both national and international.

Awards

• 1994 Nephrology Award (Dutch Society for Nephrology)
• 1996 Jon J. van Rood Award (Dutch Transplantation Society)
• 1997 Young Investigator Award (European Society Heart Lung Transplantation)
• 1998 International Young Investigator Award (American Society Transplant Physicians)
• 2000 International Young Investigator Award (American Society of Transplantation)
• 2005 Outstanding Speaker Award (American Association for Clinical Chemistry)
• 2009 Visiting Professor Nephrology West China Medical School Chengdu (China)
• 2010 Visiting Professor (Kathleen Valles Chair) St George’s Medical School London (UK)
• 2011 Teacher of the year award (medical students – Erasmus University Rotterdam)

Vision Statement

Therapeutic drug monitoring and analysis+consulting for clinical toxicology are forms of personalized medicine “avant la lettre”. IATDMCT has promoted the individualization of treatment before the term personalized medicine had even been invented. Our strength is the analytical expertise and translation of laboratory results into practical treatment recommendations . My mission will be to promote the added value of our contribution, to increase the visibility of IATDMCT and to increase involvement of clinicians into our Association. 

Professor Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan. He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. He has been studying clinical pharmacokinetics and pharmacodynamics mainly in oncology and infectious diseases. His modeling and simulation studies on population pharmacokinetics and pharmacodynamics were applied to new drug development as well as rational use for routine patient care. He also investigates multi-omics biomarkers such as genomics, proteomics and metabolomics as factors causing individual variation in drug response. He is distinguished as one of the "ISI Highly Cited Researchers."

Employment

• 1998-present, Professor, Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Japan
• 1998-2007, Director of Hospital Pharmacy, Keio University Hospital, Japan
• 1993-1998, Associate Professor and Vice Director, Department of Pharmacy, Kobe University Hospital, Japan
• 1991-1992, Honorary Research Fellow, School of Pharmacy, University of Manchester, U.K.
• 1990-1993, Lecturer, Department of Pharmacy, Kyoto University Hospital
• 1985-1990, Instructor, Department of Pharmacy, Kyoto University Hospital

Education & Certification

• Board Certified Senior Clinical Pharmacist (BCSCP), Japanese Society of Clinical Pharmacology and Therapeutics
• Board Certified Clinical Pharmacist (BCCP), Japanese Society of Clinical Pharmacology and Therapeutics
• JSPHCS-certified Senior Oncology Pharmacist (JSOP), Japanese Society of Pharmaceutical Health Care and Sciences
• Board Certified Oncology Pharmacy Specialist (BCOPS), Japanese Society of Hospital Pharmacists
• Pharmacist License of Japan • 1983, Ph.D. from Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
• 1980, MSc from Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
• 1978, BSc from Faculty of Pharmaceutical Sciences, Kyoto University, Japan

Professional Activities

• 2013-2015, IATDMCT Secretary
• 2015-, Chair of Scientific Committee “TDM in Oncology”
• 2017, Chairman, 15th IATDMCT Congress 2017 in Kyoto
• Editorial Board, Therapeutic Drug Monitoring • 2005-2011, President, Japanese Society of Therapeutic Drug Monitoring (JSTDM)
• Plenary Lecturer at 12th Congress of IATDMCT 2011 in Stuttgart
• Invited speaker at IATDMCT Regional Meeting in Sibiu, 2014
• Invited speaker at IATDMCT Regional Meeting in China, 2010
• Symposium speaker and organizer at IATDMCT (1995 in Vienna, 1999 in Cairns, 2009 in Montreal)
• Number of peer reviewed original articles: 159
• Book chapters and Review articles: 190
• Invited lectures at international conferences: 39
• Invited lectures at Japanese national conferences: 108
• Dr. Tanigawara is distinguished as “Highly Cited Researcher” by Thomson Reuters ISI database. His research interests include clinical pharmacokinetics, pharmacodynamics and pharmacogenomics and their applications to TDM. He also investigates multi-omics biomarkers by means of MS-based proteomics and metabolomics.

Other academic and professional appointments:

• 2006-present, President, Population Approach Group in Japan
• 2007-2009, Delegate for the Board of Pharmaceutical Sciences, International Pharmaceutical Federation (FIP)
• 2005-2008 and 2010-2014, Executive Board member, Japanese Society of Clinical Pharmacology and Therapeutics
• 2008-present, Executive Board member, Japanese Society of Pharmaceutical Health Care and Science
• 2007-2009, Executive Board member, The Pharmaceutical Society of Japan • 2005-present, Council member, Japanese Society of Clinical Oncology
• 2007-present, Council member, Japanese Society of Medical Oncology
• 2009-present, Council member, Japanese Cancer Association
• 2003-present, Council member, Japanese Society of Chemotherapy
• 2003-present, Council member, Japanese Society for Pharmacoepidemiology
• 2002-present, Associated Editor, Cancer Science
• 2005-present, Editorial Board, Japanese Journal of Clinical Oncology
• 2006-present, Editorial Board, International Journal of Clinical Oncology
• 2010-present, Editorial Board, The Japanese Journal of Antibiotics
• 1999-2001, Editorial Board, European Journal of Pharmaceutical Sciences

Vision Statement

As the current Secretary, I have been working hard to expand the IATDMCT network worldwide. During last 2 years, the Association has significantly grown due to the increased number of members particularly in Asian region. I am pleased to make efforts to contribute to the IATDMCT as Secretary.

Gwendolyn A. McMillin received a BA from Grinnell College, in Grinnell, IA, and a PhD in pharmacology and toxicology from the University of Utah, in Salt Lake City, UT. She completed post-doctoral training in Clinical Chemistry through the University of Utah, and is certified by the American Board of Clinical Chemistry (ABCC) in the areas of Clinical Chemistry and Toxicological Chemistry. She is currently an Associate Professor (clinical) of Pathology at the University of Utah, and is a Medical Director at ARUP Laboratories, responsible for the areas of Clinical Toxicology and Pharmacogenomics.

Dr McMillin is actively involved in professional associations. For example, she served as Chair of the TDM/Toxicology Division of the American Association for Clinical Chemistry (AACC), Chair of the Toxicological Chemistry exam and Continuing Education Committee for the American Board of Clinical Chemistry (ABCC), a Member of the Toxicology Resource Committee for the College of American Pathologists (CAP), and is co-Chair of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology's (IATDMCT) 2013 Congress. She was also involved in forming the Personalized Medicine Division of the AACC. Dr McMillin serves as an Editorial Board member for professional journals such as Therapeutic Drug Monitoring and the Journal of Analytical Toxicology, and has published nearly 100 original research manuscripts, review articles, and book chapters. Her research is focused on evaluating and assuring clinical utility of drug testing and pharmacogenomics, funded by several commercial contracts and federal grants.

Employment

• 2003-Present:  Medical Director, Toxicology and Pharmacogenomics, ARUP Laboratories, Inc., Salt Lake City, UT, USA
• 2014-Present:  Professor (Clinical), University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA
• 2010-2014:  Associate Professor (Clinical), University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA
• 2004-2010:  Assistant Professor (Clinical), University of Utah, School of Medicine, Department of Pathology, Salt Lake City, UT, USA
• 1996-2001:  Medical Director, Toxicology and Pharmacogenomics, ARUP Laboratories, Inc., Salt Lake City, UT, USA
• 1994-1996: Senior Scientist, University of Utah, Department of Pharmacology and Toxicology, Anticonvulsant Drug Development Program, Salt Lake City, UT, USA

Education & Certification

• 2005: Diplomate certification through American Board of Clinical Chemistry in Toxicological Chemistry
• 2004: Diplomate certification through American Board of Clinical Chemistry in Clinical Chemistry
• 1994: Ph.D. awarded in Pharmacology through the University of Utah, College of Pharmacy, Salt Lake City, UT, USA
• 1989: B.A. awarded in Psychology through Grinnell College, Grinnell, IA, USA

Professional Activities

Activities in IATDMCT:

• Current Treasurer; Co-chair of the 2013 annual meeting (SLC, UT);
• Contributing member of the Clinical Toxicology/Drugs of Abuse Committee;
• Invited speaker (DUPHAT 2014, IATDMCT 2015)

Activities in AACC (American Association for Clinical Chemistry):

• Current vice-chair of the 2016 annual meeting (Philadelphia, PA);
• Current officer in the Personalized Medicine Division;
• Former chair of the TDM/Toxicology Division (2009-2014);
• Symposium coordinator for annual meeting (2010);
• Chair nominating committee (2009-2010);
• Invited speaker at several annual and regional meetings

Activities in CAP (College of American Pathologists):

• Current member of the Toxicology Resource Committee and Pharmacology Working Group;
• Invited speaker at several annual meetings

Activities in ABCC (American Board of Clinical Chemistry):

• Board member, chair of Toxicology exam committee (2007-2012)

Editorial Board Member: Therapeutic Drug Monitoring; Journal of Analytical Toxicology

Active publication record:
I have authored/published in excess of 70 original manuscripts; 10 review articles; 25 book chapters; and 150 abstracts

My experience as IATDMCT Treasurer since 2013 has prepared me to serve on the Council.  I am organized and successful in completing projects in a timely manner, and I am both excited and privileged to have opportunity to continue serving the organization by managing the finances for another term. 

Mercè Brunet is Professor of Pharmacology and Toxicology at the University of Barcelona; Medical School of Barcelona. She is currently the Head of Pharmacology and Toxicology in the Biologic Diagnostic Center of the Hospital Clínic of Barcelona. She got her Ph.D. in Pharmaceutical Sciences from Barcelona University in 1980.

Mercè Brunet's main research interests are focus on treatment personalization, mainly concerning the measurement of biomarkers that may reflect immunosuppressive drugs’ exposure and effect, using pharmacokinetic, pharmacogenetic and pharmacodynamic approaches. Recently most of her work is dedicated to new pharmacokinetic/ pharmacodynamics monitoring strategies for antitumor drugs. She has published over 105 original articles in peer-reviewed international journals and 9 book chapters.

Employment

• Head of Pharmacology and Toxicology. Biologic Diagnostic Center. Hospital Clínic, University of Barcelona, Spain (2004-present).
• Professor of Pharmacology and Toxicology, Medical School, University of Barcelona (1996- present).
• Staff Member: Pharmacology Laboratory, 1987-2003, Hospital Clínic. University of Barcelona.
• Research fellow: Hospital Clínic, 1982-1986. University of Barcelona.
• Associate Professor of Medicine, 1994- 1996. University of Barcelona.

Education & Certification

• PhD Pharmacology, University of Barcelona (1993), Doctoral Thesis, Project: “Contribución al estudio de la toxicidad de los fármacos antiepilépticos. Efectos adversos sobre el. metabolismo de los esteroides”.
• B.S.C. University of Barcelona. School of Pharmacy (1980).
• Specialist in Biochemical Analysis. University of Barcelona (1990).
• Pharmacist Assistant, School of Pharmacy, University of Barcelona (1983).
• Good Laboratory Practices GLPs: Certified of Auditor (2000).

Professional Activities

IATDMCT Awards

• Director of Education of the IATDMCT Council (2013-2015).
• Councilor of the IATDMCT Council (2009-2011).
• Leader of the Biomarkers Working Group (BWG) of the Scientific Committee of Immunosuppressive Drugs at the IATDMCT. (2010-2015).
• Member of Scientific Committee of Immunosuppressive Drugs (2007-2015).

Activities in IATDMCT

• Coordinator of the Special issue of the First Consensus Document for promising biomarkers of immunosuppression in clinical transplantation: methods standardization and validation. Co- Educational Activity Project of the Biomarker Working Group. Project Coordination: Mercè Brunet, Michael Oellerich and Pierre wallemacq (2014-2015).
• Director of the IV Symposium on Biomarkers of Immunosuppression and Clinical Outcome in Transplantation: New Approaches on TDM of Immunosuppressive Drugs. Educational activity of the BWG of the Scientific Committee of IDs. IATDMCT. Scientific Coordination: M. Brunet and P. Wallemacq on behalf of the Biomarkers Working Group (BWG). Barcelona, December 11-12 2014.
• The Directors and Education designed a survey, to know the most important topics in education for our members, provided in the resources area of the IATDMCT website which has been active during February 2014 and was completed by 120 members.
• 14th IATDMCT Congress, the Netherlands, Rotterdam 2015. A proposal of the ISDs committee with topics to be included in specific Symposiums, such us biomarkers in transplantation, in the scientific program.Coordinators: Teun van Gelder, Maria Shipkova, Dennis Hesselink, Mercé Brunet.
• Member of the Scientific Committee of Experts of the 19 Congress of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Stuttgart November 2013.
• European Symposium on Clinical Immunosuppression Monitoring of Biomarkers in Transplantation (under the auspices of IATDMCT). Symposium Coordinator: M: Brunet. Speakers: Expert members of the IATDMCT (IDs Scientific Committee). Barcelona 2011. Published in Compass.
• Lecturre at IATDMCT Congress SLC 2013. Symposium S2502: Pharmacodynamic Monitoring Biomarkers of Immunosuppression in Transplantation. Mercè Brunet, Moderator: Leslie M.

Other Awards

• Secretary of the Council of the Spanish Society of Pharmacogenetics and Pharmacogenomics. (2012-present).
• Secretary of the Catalan Scientific Society of Transplantation. Academy of Medical Sciences of Catalonia and the Balearic Islands. (2009-present).
• Member of the Scientific Committee of Immunology of the Spanish Society of Transplantation (SET) (2014-2018).
• Member of the International Transplant Society (2002 - present).
• Member of CIBERehd-Networked Biomedical Research Center: Hepatic and Digestive Diseases.
• Member of the Reial Academia de Medicina de Catalunya I Balears.
• Member of the Editorial Boards of International Journals such us Therapeutic Drug Monitoring (TDM), Trends in Transplantation (TT).

Other Professional / Educational Activities (2010-2015)

• Master Coordinator: Master in Translational Medicine (Module1). University of Barcelona.
  www.ub.edu/medicina/masters/traslacional/.
• Course Director: The role of Mass Spectrometry in the Clinical Diagnostic Laboratories. Technical advances and new applications. Farmacologia i Toxicologia. Centre de Diagnòstic Biomèdic. Aula Clínic. Hospital Clínic. University of Barcelona. October 2011, October 2013.
• Scientific Organizing Committee: 12 Congres de la Societat Catalana de Trasplantament. Barcelona March 2013.
• Scientific Organizing Committee: 13 Congres de la Societat Catalana de Trasplantament. Barcelona March 2015.
• Scientific Organizing Committee of 4th and 5th Congreso de la Sociedad Española de Farmacogenética y Farmacogenómica (SEFF). Bilbao June 2013, Madrid April 2015.
• Scientific Organizing Committee: Curs Pre-congres de la Societat Catalana de Trasplantament (Formació de residents): 2 y 3 Curso práctico de trasplante de órganos sólidos. Barcelona, March 2013; March 2015.
• Lectures at Congreso Sociedad Española de Química Clínica (SEQC) Octubre 2014.
• Invited expert at a meeting “Graft-derived circulating cell-free DNA as a marker of graft integrity using Droplet Digital™ PCR” organized by M. Oellerich and BioRad (2014).

Publications

• Published over 150 original articles in peer-reviewed international journals and 12 book chapters.

Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.

From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland. 
Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of 100 peer-reviewed publications, 8 book chapters and 50 published oral or poster presentations.

Dr Rentsch is currently the head of the Swiss Society of Clinical Chemistry and she is a member of the IATDMCT, the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh), and several other local professional organizations. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.

Employment

• Since 2014 Head of Laboratory Medicine, University Hospital Basel, Switzerland
• Since 2011 Head of the Clinical Chemistry division, University Hospital Basel, Switzerland
• 2004-2011 Deputy Head of the Institute for Clinical Chemistry, University Hospital Zurich, Switzerland
• 1994-2011 Head of the laboratory for drug analysis and clinical toxicology, Institute for Clinical Chemistry, University Hospital Zurich, Switzerland
• 1991-1994 Scientist at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland
• 1990-1991 Head of the Laboratory for Special Analyses at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland
• 1989-1990 Scientist at the Institute for Clinical Chemistry at the University Hospital Zürich, Switzerland

Education & Certification

• 2012 Adjunct professor („Titularprofessorin“), Medical faculty, University Basel, Switzerland
• 2010 Adjunct professor („Titularprofessorin“), Medical faculty, University Zürich, Switzerland
• 2007 Certification as „Clinical Toxicologist GTFCh“
• 2007 Habilitation for Clinical Chemistry at the Medical Faculty of the University Zürich, Switzerland
• 2003 Habilitation for Clinical Chemistry at the Department of Chemistry and Applied Biosciences, ETHZ, Zurich, Switzerland
• 1996 PhD dissertation at the Institute of Pharmaceutical Sciences, ETHZ, Zurich, Switzerland
• 1991 Certification as “Specialist for Laboratory Medicine” awarded by the FAMH (Swiss Association of the Heads of Medical Laboratories)
• 1988 Master of Science in Pharmacy, Swiss Federal Institute of Technology Zurich, (ETHZ), Switzerland; awarded pharmacist’s license

Professional Activities

Memberships and Activities in Scientific Societies

• International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
• The International Association of Forensic Toxicologists (TIAFT)
• American Association for Clinical Chemistry (AACC) - Society of Toxicological and Forensic Chemistry (GTFCh)
• Swiss Society of Clinical Chemistry (SSCC)
• Swiss Chemical Society (SCS)
• Swiss Group of Mass Spectrometry (SGMS)
• Swiss Association of the Heads of Medical Laboratories (FAMH)
• Swiss Federation of Pharmacists (pharmaSuisse)

Executive and committee positions held

• Vice president of the Society of Toxicological and Forensic Chemistry (GTFCh) (since 2015)
• Member of the GTFCh committee “Clinical Toxicology” (since 2001)
• Chair of the SSCC committee “Drug Monitoring” (since 2003)
• President of the Swiss Society of Clinical Chemistry (SSCC) (2009-2014)
• Vice president of the SSCC and chair of the scientific committee (2006-2008)
• Member of the board of the Division “Analytical Chemistry” of the Swiss Chemical Society (2006-2008)

Activities for IATDMCT

• Councillor of the IATDMCT 2007 – 2015
• Member of the Clinical Toxicology/Drugs of Abuse Committee (since 2006)
• Member of the Local Organizing Committee of the Stuttgart Meeting (responsible for roundtables). 2011
• Member of the Scientific Board of the Basle Meeting (responsible for CT breakfast roundtables), 2003

Number of Publications

• > 120 peer reviewed original papers and invited reviews
• > 60 published oral or poster presentations
• 8 book chapters Speaking engagements:
• > 100 invited lectures (universities, national and international meetings)

Professional Appointments

• Referee of scientific journals (e.g Clin Chem, J Chromatogr A and B, J Mass Spectrom, Anal Bioanal Chem, Anal Chem)
• Lecturer University Basel, Pharmaceutical Sciences: “Clinical Chemistry” including Therapeutic Drug Monitoring and Clinical Toxicology (3rd year Bachelor, 1st year Master)
• Lecturer University Basel Medical School: “Chemistry in Blood” (2nd year Bachelor)
• Lecturer Swiss Federal Institute of Technology (ETHZ), Medical and Industrial Pharmaceutical Scienses: “Bioanalytics” in the module “Clinical research and development” (1st year Master)
• Lecturer Swiss Federal Institute of Technology (ETHZ), Pharmaceutical Sciences: “Clinical Chemistry” including Therapeutic Drug Monitoring and Clinical Toxicology (3rd year Bachelor, 1st year Master) (until 2012)
• Lecturer University Zurich Medical School: “Therapeutic Drug Monitoring” (1st year Master) (ongoing), Clinical Toxicology (2nd year Bachelor), Clinical Chemistry (2nd year Bachelor, 1st year Master) (until 2011)

Employment

• 2003- Senior scientist and head TDM/Tox section, Institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany
• 1999- 2002 Resident Dept. of Clinical Chemistry, University Göttingen, Germany
• 1995-1999 Postdoctoral fellow, Dept. of Clinical Chemistry, University Göttingen, Germany
• 1992-1995 Resident Dept. of Clinical Chemistry, University Sofia, Bulgaria
• 1991-1992 Resident Dept. Internal Medicine, University Sofia, Bulgaria

Education & Certification

Academic Degrees

• Dr. med. University Göttingen, Germany, 2002
• D-r (BG)., University Sofia, Bulgaria, 1990,

Professional Registrations                        

• Fellow European Board of Laboratory Medicine/Medical Biopathology (F.E.B.L.M./M.B.), 2013
• Clinical Pathology Consultant, 1996

Professional Activities  

Professional Society Memberships

• Vereinte Deutsche Gesellschaft für Laboratoriumsmedizin und Klinische Chemie(DGKL)
• International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
• Transplantation Society

Publications

93 articles contributed to scientific journals on the following topics: therapeutic drug monitoring, drug metabolism, drug toxicity, development and evaluation of analytical methods, organ function tests, biomarkers of drug effects.

Stipends and Awards

• 2015 Grant from the Federal Ministry of Education and Research “Validation of GcfDNA based diagnostic test to detect organ damage after kidney transplantation”
• 2011 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Analytical validation of biomarker assays in transplantation medicine
• 2005 Young Investigator Award of the International Society for Therpaeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
• 2004 Grant of the Pathobiochemistry and Molecular Diagnostics Foundation, DGKL, Acyl glucoronides of mycophenolic acid
• 2002 Grant of the University Göttingen, Germany, Acyl glucuronide of mycophenolic acid
• 1998 Stipend Volkswagen Foundation, Germany, Metabolism of immunosuppressants
• 1996 Stipend Otvoreno Obschtestvo, Bulgaria, Pharmacokinetics of Taxol
• 1995 Tempus Phare stipend of the EU, Therapeutic Drug Monitoring

Varia

• Past Chair of the IATDMCT Immunosuppressive Drugs Scientific Committee
• Vice-Chair IATDMCT Communication Committee
• Coordinator “TDM of Everolimus” Consensus Project
• Past Editor in Chief of the IATDMCT Newsletter “Compass”
• Member of the Editorial Boards of Therapeutic Drug Monitoring (TDM)
• Reviewer of publication for: Journal of Chromatography, Clinical Chemistry, Clinical Biochemistry, Clinica Chimica Acta, Transplant International, etc.

Current Appointments

• Senior Specialist in Clinical Microbiology and Infectious Diseases St. Vincent's Hospital, Sydney (1985 - to date)
• Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group, St. Vincent’s Hospital, Sydney (2012 – to date)
• Visiting Medical Officer St. Vincent's Private Hospital, Sydney (1985 – to date)
• Visiting Medical Officer Sacred Heart Hospice, Sydney (1985 – to date)
• Conjoint Associate Professor, School of Medicine, University of New South Wales (2000 – to date)
• Adjunct Professor, Faculty of Science University of Technology, Sydney (2002 -to date)
• Associate Editor, Transplantation (2014 – to date)

Certifications

• Fellow of the Royal College of Pathologists of Australasia (FRCPA) 1986
• Fellow of the Royal Australasian College of Physicians (FRACP) 1985
• Bachelor of Medicine and Bachelor of Surgery, Honours Class I 1977
• Bachelor of Science (Medicine) Honours Class I 1974

Current Memberships - Professional Societies

• Royal Australasian College of Physicians
• Royal College of Pathologists of Australasia
• Australasian Society for Infectious Diseases
• Australasian Society for HIV Medicine
• American Society for Microbiology
• Australasian Society for Antimicrobials
• Infectious Diseases Society of America
• International Society for Heart and Lung transplantation
• International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• Transplant Infectious Diseases
• European Society for Clinical Microbiology and Infectious Diseases
• The Transplant Society
• Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

• 1986- Member, Drug and Therapeutics Committee, St. Vincent's Hospital
• 1988 - Accreditor, National Association of Testing Authorities
• 1989-97 Member, N.S.W. State Committee, Royal Australasian College of Physicians
• 1990- Examiner, Royal Australasian College of Pathologists
• 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
• 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
• 1997-99 President, Australasian Society for HIV Medicine
• 2000-10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
• 2009-13 Co-chair, Australian and New Zealand Mycoses Interest Group
• 2010 - Examiner, Royal Australasian College of Physicians
• 2012- Scientific Committee member (HIV and Infectious Diseases), International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• 2012- Scientific Committee member, International Society for Heart and Lung Transplantation • 2012- Scientific Committee member, Transplant Infectious Diseases
• 2013- President, Transplant Infectious Diseases
• 2013- Board Member, Medical Advances without Animals
• 2014 - Visiting Lecturer, The Academy of Medicine, Singapore
• 2014- Visiting International Professor, Royal College of Pathologists of Australasia

• Approximately 160 publications in refereed journals
• Joint lead, IATDMCT Guidelines on TDM of Echinocandins
• Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device. The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients. (In press).
• Proposer and Co-Convener – joint IATDMCT/TID/The Transplant Society (TTS) Conference, Hong Kong, 2016 in conjunction with TTS Conference
• Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014), ISHAM (Melbourne 2015)
• Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013) and Penang (2014).
• Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
• Coordinator of the Clinical Stream at the forth-coming ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
• Reviewer of approximately 15 manuscripts per year for the past 5 years in local and international journals

Employment

• Division of Clinical Pharmacology
  Karolinska Institutet
  Stockholm, Sweden
• Institute of Experimental and Clinical Pharmacology and Toxicology
  Saarland University, Homburg (Germany)

Education & Certification

• Habilitation with Venia Legendi for Pharmacology & Toxicology 
• PhD
• M.Sc., Pharmacist
• Clinical toxicologist certified by GTFCh

Professional Activities

• Memberships in IADTMCT, TIAFT, GTFCh (German speaking society of forensic chemistry), DPhG (German society of pharmaceutical sciences)
• Activities in IATDMCT: Vice chair young scientist committee, Member of communication commitee
• Executive and committee positions held: TIAFT (Young scientist committee member), GTFCh (Chair of the continuous education program)
• Number of publications: over 80 PubMed-listed and peer-reviewed articles, numerous book chapters
• Speaking engagements: Several invited talks at international conferences (USA, Europe, Asia)
• Professional appointments: Clinical toxicologist GTFCh

Dr Franck Saint-Marcoux is President of the TDM group of the French Society of Pharmacology and Therapeutics (SFPT) and Chair of the IATDMCT Pharmacometrics Committee. He is currently responsible for the Pharmacology and Pharmacokinetic Unit of the Pharmacology and Toxicology department of the Limoges University Hospital (France), and is a member of the INSERM research unit "Pharmacology of the immunosuppressive drugs in transplantation" directed by Prof. Pierre Marquet.

Dr Franck Saint-Marcoux obtained a Master of Advanced Studies in Pharmacy and a PhD in Pharmacokinetic Modelling in 2004. His research activity is focused on the development of PK tools useful for routine activity of TDM, mainly immunosuppressants, but also antibiotics or anticancer drugs. He is author or co-author of over 40 papers in peer-reviewed international journals.

Employment

Franck Saint-Marcoux is currently:

• Full Professor of Toxicology; Head of the Toxicology Department of the Faculty of Pharmacy, Limoges, France
• Hospital Practitioner; Head of the Clinical and Forensic Toxicology Unit of the Pharmacology and Toxicology Department, Limoges University Hospital, France
• Member of the INSERM research unit “Pharmacology of the immunosuppressive drugs in transplantation”, Limoges University, France
  (INSERM is the French Institute of Medical and Health Research)

Education & Certification

Franck Saint-Marcoux is PharmD, PhD

• Master of Advanced Studies in Clinical Pharmacy
• PhD in Pharmacokinetic Modelling

Professional Activities

• Member of the IATDMCT since 2003
• Councillor of the IATDMCT
• Chair of the IATDMCT Pharmacometrics Committee
• Past President of the TDM group of the French Society of Pharmacology and Therapeutics
• Author or co-author of over 50 papers in peer-reviewed international journals

Christoph Seger studied Chemistry and Biochemistry at the University of Vienna, Austria (PhD 2001, University of Vienna). After focusing on NMR based structure elucidation of Natural Products and peptides (Max Planck Institute for Biochemistry, Martinsried, Germany) for several years he took up a lecturer position at the Institute of Pharmacy at the University of Graz, Austria, followed by Post-Doc appointment at the Institute of Pharmacy at the University of Innsbruck, Austria. He obtained his venia legendi (Habilitation) at the University of Innsbruck in 2008 for his research focus on Pharmaceutical Analysis.

Since 2005 he is technical head of the ISO 15189 accredited Mass Spectrometry and Chromatography laboratory at the Central Institute of Medicinal and Chemical Laboratory Diagnostics (ZIMCL) / University Hospital Innsbruck, Austria which focuses on TDM and endocrinology testing. 
Besides serving as council member for the IATDMCT, where he is also ISD scientific committee member, he is a board member of the Austrian Society for Analytical Chemistry (ASAC) and the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC). He serves as review team I / II member for the Joint Committee for Traceability in Laboratory Medicine (JCTLM) Working Group and has been appointed as PT scheme leader for drugs of the Austrian Society for Quality Assurance and Standardization of Medical-Diagnostics (ÖQUASTA). 

He is involved in academic teaching at the University of Innsbruck, the Medical University Innsbruck and the UMIT. In addition he has supervised more than a dozen BA, MS, and PhD theses projects. His publication record currently holds 60+ peer reviewed papers and reviews, about 50 conference abstracts in peer reviewed journals, 40 invited lectures and more than 130 other conference contributions (lectures, poster presentations).

Dr Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD theses and post-doc fellows. He is also head of Clinical Chemistry Department in the Cliniques universitaires St Luc, Brussels, in charge of the automated CoreLab platform as well as of the analytical biochemistry platform regrouping specific activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry and endocrinology (GC, HPLC, UPLC, LC-MSMS, GC-MS).

He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author of more than 180 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 200 conferences on invitation. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas. Pierre Wallemacq is the past-president of the Royal Belgian Society of Clinical Chemistry (SRBCC-KBVKC), and is the current president of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. He received the IATDMCT C.E. Pippenger award in 2011 for outstanding contribution to Therapeutic drug Monitoring, and was nominated member of the Royal Belgian Academy of Medicine (ARMB) in 2012.

Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.

She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.

Pierre Marquet has been a Doctor of Medicine since 1986 and obtained a master in statistics and epidemiology followed by a PhD in physiology in 1992. After several years as an assistant professor at Limoges University Hospital, he became an associate professor of pharmacology in 1998 and since 2001, has been a full professor at the Faculty of Medicine of Limoges, France. He was presented with the Young Scientist Award of the French Society of Analytical Toxicology in 1995, the IATDMCT Young Investigator Award in 2001 and C.E. Pippenger Award in 2009. At the IATDMCT, he chaired the Standard of Laboratory Practice Committee from 2001-2007, was elected Secretary in 2007 and then President-elect in 2009.

Pierre Marquet is currently:

• Director of the INSERM U850 research unit called "Pharmacology of immunosuppressive drugs in transplantation" 
  (INSERM is the French Institute of Medical and Health Research)
• Head of the "Pharmacology, Toxicology and Pharmacovigilance" Department at the University Hospital of Limoges
• Vice-President of the board of Directors of University Hospital of Limoges, in charge of research
• Member of the council of the French Society of Pharmacology and Therapeutics (SFPT)
• Coordinator of the "drugs and pharmacology" working group of the French-speaking Society of Transplantation (SFT)
• Member of several scientific committees

Pierre Marquet conducts translational research on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: new analytical methodologies for IS; metabolic, pharmacogenetic and pharmacodynamic studies of the IS; investigation of early biomarkers; epidemiological studies and clinical trials in transplant patients; and application to routine treatment personalization in transplant recipients. He has published over 160 papers in peer-reviewed, international journals. He is the coordinator of the European research program "Biomarkers of Renal Graft Injuries" (BIOMARGIN, FP7 Health).

Professor Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan. He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. He has been studying clinical pharmacokinetics and pharmacodynamics mainly in oncology and infectious diseases. His modeling and simulation studies on population pharmacokinetics and pharmacodynamics were applied to new drug development as well as rational use for routine patient care. He also investigates multi-omics biomarkers such as genomics, proteomics and metabolomics as factors causing individual variation in drug response. He is distinguished as one of the "ISI Highly Cited Researchers."

• 1978 BSc. Faculty of Pharmaceutical Sciences, Kyoto University, Japan
• 1983 Ph.D., Graduate School of Pharmaceutical Sciences, Kyoto University
• 1985-1990 Instructor, Department of Pharmacy, Kyoto University Hospital
• 1990-1993 Lecturer, Department of Pharmacy, Kyoto University Hospital
• 1991-1992 Research fellow, School of Pharmacy, University of Manchester, U.K.
• 1993-1998 Associate Professor and Vice Director, Department of Pharmacy, Kobe University Hospital, Japan
• 1998-2007 Director of Hospital Pharmacy, Keio University Hospital, Japan
• 1998-present Professor, Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Japan

Gwendolyn A. McMillin received a BA from Grinnell College, in Grinnell, IA, and a PhD in pharmacology and toxicology from the University of Utah, in Salt Lake City, UT. She completed post-doctoral training in Clinical Chemistry through the University of Utah, and is certified by the American Board of Clinical Chemistry (ABCC) in the areas of Clinical Chemistry and Toxicological Chemistry. She is currently an Associate Professor (clinical) of Pathology at the University of Utah, and is a Medical Director at ARUP Laboratories, responsible for the areas of Clinical Toxicology and Pharmacogenomics.

Dr McMillin is actively involved in professional associations. For example, she served as Chair of the TDM/Toxicology Division of the American Association for Clinical Chemistry (AACC), Chair of the Toxicological Chemistry exam and Continuing Education Committee for the American Board of Clinical Chemistry (ABCC), a Member of the Toxicology Resource Committee for the College of American Pathologists (CAP), and is co-Chair of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology's (IATDMCT) 2013 Congress. She was also involved in forming the Personalized Medicine Division of the AACC. Dr McMillin serves as an Editorial Board member for professional journals such as Therapeutic Drug Monitoring and the Journal of Analytical Toxicology, and has published nearly 100 original research manuscripts, review articles, and book chapters. Her research is focused on evaluating and assuring clinical utility of drug testing and pharmacogenomics, funded by several commercial contracts and federal grants.

Mercè Brunet is Professor of Pharmacology and Toxicology at the University of Barcelona; Medical School of Barcelona. She is currently the Head of Pharmacology and Toxicology in the Biologic Diagnostic Center of the Hospital Clínic of Barcelona. She got her Ph.D. in Pharmaceutical Sciences from Barcelona University in 1980.

Mercè Brunet is also currently:

• Coordinator of the Biomarker Working Group (BWG) of the Scientific Committee of Immunosuppressive Drugs at the IATDMCT.
• Coordinator of the Master in Translational Medicine (Module1), of the University of Barcelona, School of Medicine.
• Secretary of the Council of the Sociedad Española de Farmacogenética y Farmacogenómica (SEFF).
• Secretary of the Council of the Catalan Transplantation Society (CTS).
• Member of CIBERehd-Networked Biomedical Research Center: Hepatic and Digestive Diseases
• Member of the International Transplant Society.
• Member of the European Transplant Society.
• Member of the Reial Academia de Medicina de Catalunya I Balears.
• Member of the Editorial Boards of International Journals such us Therapeutic Drug Monitoring (TDM), Trends in Transplantation (TT).

Mercè Brunet's main research interests are focus on treatment personalization, mainly concerning the measurement of biomarkers that may reflect immunosuppressive drugs’ exposure and effect, using pharmacokinetic, pharmacogenetic and pharmacodynamic approaches. Recently most of her work is dedicated to new pharmacokinetic/ pharmacodynamics monitoring strategies for antitumor drugs. She has published over 105 original articles in peer-reviewed international journals and 9 book chapters.

Professor Vanessa Steenkamp obtained her PhD in Clinical Chemistry (Toxicology of traditional herbal remedies). Presently she heads the Phytomedicine Unit, Department of Pharmacology, University of Pretoria, South Africa. She is Past-President of the South African Association of Clinical Biochemistry, Vice-President of the Toxicology Society of South Africa and Secretary-General of the South African Association of Basic & Clinical Pharmacology. Internationally she serves as vice-chair of the IATDMCT Clinical Toxicology committee and participates in the Standards of Laboratory Practice committee. She is a member of the nominating committee of the International Union of Toxicology and serves on the Executive Committee of the IFCC. She strives to better health care provision and with her dedication to the African Federation of Clinical Chemistry, regional federation of the IFCC, of which she is currently President, was inaugurated in 2009.

Vanessa is author/co-author of >70 scientific papers and 3 book chapters. Awards for her research both nationally & internationally, amongst others, include: the prestigious Friedel Sellschop award and Exceptional Young Researcher of the University of Pretoria, the Young Scientist Award from the IATDMCT and AACC. Reviewer for 18 international peer-reviewed journals and on the editorial board of 4 journals. She has lectured worldwide and in 2010 was awarded the IATDMCT travelling lectureship where she presented toxicology lectures in Chile. Vanessa is registered with the Health Professions Council of South Africa as a medical scientist, the South African Council for Natural Scientific Professions (SACNSP) as a Professional Natural Scientist and is a rated scientist with the National Research Foundation. She serves on the Professional Advisory Committee of SACNSP. At the University she serves on various academic and research committees. She has supervised 28 post graduate students to graduation and 10 currently under her supervision.

Eberhard Wieland is Professor of Clinical Chemistry and Laboratory Medicine . He is Medical Director and head of the Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany.

Dr. Wieland received his MD in Biochemistry from the Ruprecht-Karls-University, Heidelberg in 1982. Between 1983 and 1985 he was resident in Internal Medicine and received a training in Medical Microbiology at the University Hospital, Heidelberg.

In 1985 he was awarded a research fellowship by the Volkswagen foundation which he spent between 1985 and 1987 at the Department of Endocrinology and Metabolism of the University of California, San Diego, USA.

From 1987 to 1993 he received his training in Clinical Chemistry and Laboratory Medicine at the Georg-August-University Goettingen. In 1993 he was certified in Clinical Chemistry and became consultant in Laboratory Medicine. In 2000 he was appointed Professor of Clinical Chemistry.

Dr. Wieland became Medical Director and head of the Central Institute of Clinical Chemistry and Laboratory Medicine of Klinikum Stuttgart in 2003. He is teaching Clinical Chemistry and Laboratory Medicine at the Eberhard-Karls-University in Tuebingen.

Dr. Wieland conducts research in pharmacokinetics and pharamacodynamics of immunosupressant drugs. His current research interest is in biomarkers to complement TDM. In addition, he performs funded research on oxidative stress in transplantation medicine and atherosclerosis. Dr. Wieland has contributed over 90 articles for peer reviewed scientific journals and 16 book chapters on the topics TDM, atherosclerosis, oxidative stress and biomarkers. He has presented more than 160 lectures and posters at national and international events. He is an editorial board member of Clinical Biochemistry, Canada; Folia Medica Plovid, Bulgaria; and Journal of Laboratory Medicine, Germany. He is also an active referee for German accreditation bodies.

Olof Beck studied chemistry at the Royal Institute of Technology in Stockholm and received his Ph.D. degree in 1982 after working at the Karolinska Institute with studies on biogenic amines using gas chromatography-mass spectrometry methods. After a post-doctoral period at Stanford University and two years in pharmaceutical industry he returned to Karolinska Institute and department of Clinical Pharmacology in 1988. Dr. Beck is at present adjunct professor and laboratory director of the Pharmacology Laboratory comprising TDM, genotyping, clinical and workplace drugs-of-abuse testing, sports doping control and contract analyses in clinical trials. He has been active assessor in laboratory accreditation in the Nordic countries.

Research activities have resulted in about 200 publications. Areas of interest are method developments in pharmacology and toxicology with special focus on mass spectrometry, alcohol biomarkers and toxicology. Most recent work is focused on Internet drugs, breath testing for abused drugs and alcohol biomarker phosphatidylethanol.

Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.

From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland. 
Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of 100 peer-reviewed publications, 8 book chapters and 50 published oral or poster presentations.

Dr Rentsch is currently the head of the Swiss Society of Clinical Chemistry and she is a member of the IATDMCT, the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh), and several other local professional organizations. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.

Dr Franck Saint-Marcoux is President of the TDM group of the French Society of Pharmacology and Therapeutics (SFPT) and Chair of the IATDMCT Pharmacometrics Committee. He is currently responsible for the Pharmacology and Pharmacokinetic Unit of the Pharmacology and Toxicology department of the Limoges University Hospital (France), and is a member of the INSERM research unit "Pharmacology of the immunosuppressive drugs in transplantation" directed by Prof. Pierre Marquet.

Dr Franck Saint-Marcoux obtained a Master of Advanced Studies in Pharmacy and a PhD in Pharmacokinetic Modelling in 2004. His research activity is focused on the development of PK tools useful for routine activity of TDM, mainly immunosuppressants, but also antibiotics or anticancer drugs. He is author or co-author of over 40 papers in peer-reviewed international journals.

Christoph Seger studied Chemistry and Biochemistry at the University of Vienna, Austria (PhD 2001, University of Vienna). After focusing on NMR based structure elucidation of Natural Products and peptides (Max Planck Institute for Biochemistry, Martinsried, Germany) for several years he took up a lecturer position at the Institute of Pharmacy at the University of Graz, Austria, followed by Post-Doc appointment at the Institute of Pharmacy at the University of Innsbruck, Austria. He obtained his venia legendi (Habilitation) at the University of Innsbruck in 2008 for his research focus on Pharmaceutical Analysis.

Since 2005 he is technical head of the ISO 15189 accredited Mass Spectrometry and Chromatography laboratory at the Central Institute of Medicinal and Chemical Laboratory Diagnostics (ZIMCL) / University Hospital Innsbruck, Austria which focuses on TDM and endocrinology testing. 
Besides serving as council member for the IATDMCT, where he is also ISD scientific committee member, he is a board member of the Austrian Society for Analytical Chemistry (ASAC) and the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC). He serves as review team I / II member for the Joint Committee for Traceability in Laboratory Medicine (JCTLM) Working Group and has been appointed as PT scheme leader for drugs of the Austrian Society for Quality Assurance and Standardization of Medical-Diagnostics (ÖQUASTA). 

He is involved in academic teaching at the University of Innsbruck, the Medical University Innsbruck and the UMIT. In addition he has supervised more than a dozen BA, MS, and PhD theses projects. His publication record currently holds 60+ peer reviewed papers and reviews, about 50 conference abstracts in peer reviewed journals, 40 invited lectures and more than 130 other conference contributions (lectures, poster presentations).